A Pilot Controlled Trial of Bupropion XL Versus Escitalopram in Generalized Anxiety Disorder

Name: A Pilot Controlled Trial of Bupropion XL Versus Escitalopram in Generalized Anxiety Disorder
SKU: 4109
Price: 30.00 USD
Availability: InStock

$30.00

Alexander Bystritsky, MD Link

ORIGINAL RESEARCH

Efficacy of Duloxetine for the Treatment of Depression: Relationship to Most Recent Antidepressant Trial

Timothy Petersen, PhD, Roy H. Perlis, MD, Chris Ticknor, MD, Jim Lohr, MD, H. Brent Solvason, MD, PhD, John P. O’Reardon, MD, Madelaine M. Wohlreich, MD, Charissa Andreotti, ScB, Michael Wilson, MS, and Maurizio Fava, MD

Want a discount? Become a member by purchasing Psychopharmacology Bulletin Subscription - Individual!

Categories: Psychopharmacology Bulletin, VOL 41 No. 1 Articles Tags: alexander-bystritsky, ba, bupropion-hydrochloride, generalized-anxiety-disorder, jamie-d-feusner, lauren-kerwin, md, phd, psychopharmacology

Description

Description

Alexander Bystritsky, MD Link

ORIGINAL RESEARCH

Efficacy of Duloxetine for the Treatment of Depression: Relationship to Most Recent Antidepressant Trial

Timothy Petersen, PhD, Roy H. Perlis, MD, Chris Ticknor, MD, Jim Lohr, MD, H. Brent Solvason, MD, PhD, John P. O’Reardon, MD, Madelaine M. Wohlreich, MD, Charissa Andreotti, ScB, Michael Wilson, MS, and Maurizio Fava, MD

A Pilot Controlled Trial of Bupropion XL Versus Escitalopram in Generalized Anxiety Disorder

Alexander Bystritsky, MD Link

ORIGINAL RESEARCH

Efficacy of Duloxetine for the Treatment of Depression: Relationship to Most Recent Antidepressant Trial

Timothy Petersen, PhD, Roy H. Perlis, MD, Chris Ticknor, MD, Jim Lohr, MD, H. Brent Solvason, MD, PhD, John P. O’Reardon, MD, Madelaine M. Wohlreich, MD, Charissa Andreotti, ScB, Michael Wilson, MS, and Maurizio Fava, MD

Description

Alexander Bystritsky, MD Link

ORIGINAL RESEARCH

Efficacy of Duloxetine for the Treatment of Depression: Relationship to Most Recent Antidepressant Trial

Timothy Petersen, PhD, Roy H. Perlis, MD, Chris Ticknor, MD, Jim Lohr, MD, H. Brent Solvason, MD, PhD, John P. O’Reardon, MD, Madelaine M. Wohlreich, MD, Charissa Andreotti, ScB, Michael Wilson, MS, and Maurizio Fava, MD

Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Schizophrenia or Schizoaffective Disorder

Nienke Dekker, MD: Cessation of Cannabis Use by Patients with Recent-Onset Schizophrenia and Related Disorders

Long-Acting Injectable Paliperidone Palmitate: A Review of Efficacy and Safety

C. Lindsay DeVane, PharmD: An Explanation of the Second-Dose Effect in Pharmacokinetics and Its Meaning for Clinical Psychopharmacology

A Pilot Controlled Trial of Bupropion XL Versus Escitalopram in Generalized Anxiety Disorder

Alexander Bystritsky, MD Link

ORIGINAL RESEARCH

Efficacy of Duloxetine for the Treatment of Depression: Relationship to Most Recent Antidepressant Trial

Timothy Petersen, PhD, Roy H. Perlis, MD, Chris Ticknor, MD, Jim Lohr, MD, H. Brent Solvason, MD, PhD, John P. O’Reardon, MD, Madelaine M. Wohlreich, MD, Charissa Andreotti, ScB, Michael Wilson, MS, and Maurizio Fava, MD

Description

Alexander Bystritsky, MD Link

ORIGINAL RESEARCH

Efficacy of Duloxetine for the Treatment of Depression: Relationship to Most Recent Antidepressant Trial

Timothy Petersen, PhD, Roy H. Perlis, MD, Chris Ticknor, MD, Jim Lohr, MD, H. Brent Solvason, MD, PhD, John P. O’Reardon, MD, Madelaine M. Wohlreich, MD, Charissa Andreotti, ScB, Michael Wilson, MS, and Maurizio Fava, MD

Related products

Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Schizophrenia or Schizoaffective Disorder

Nienke Dekker, MD: Cessation of Cannabis Use by Patients with Recent-Onset Schizophrenia and Related Disorders

Long-Acting Injectable Paliperidone Palmitate: A Review of Efficacy and Safety

C. Lindsay DeVane, PharmD: An Explanation of the Second-Dose Effect in Pharmacokinetics and Its Meaning for Clinical Psychopharmacology